The document summarizes a presentation on the pharmaceutical regulatory science landscape in 2015. It discusses:
1) Changes and emerging trends in regulatory sciences, including increased globalization and harmonization efforts.
2) Quality metrics and using data to understand industry performance and identify issues.
3) Shifting business models, including more outsourcing and the need for continuous quality improvements.
4) Ensuring data integrity and addressing challenges like lack of integrity raising doubts about safety.
The Statisticians Role in Pharmaceutical DevelopmentAshwani Dhingra
Statistics plays an important role in drug development. Its use is necessary for planning and analysing trials and using statistics correctly is crucial for the success of drug development programs.
The Statisticians Role in Pharmaceutical DevelopmentAshwani Dhingra
Statistics plays an important role in drug development. Its use is necessary for planning and analysing trials and using statistics correctly is crucial for the success of drug development programs.
Process Analytical Technology, Quality by Design & PharmacogenomicsAjaz Hussain
Keynote address at the 2013 Scientific Conference of the Nigerian Association of Pharmacists and Pharmaceutical Scientists in the Americas (NAPPSA). The lecture attempts to 'connect the dots' between PAT and QbD to Pharmacogenomics in the context of the authors experience at the US FDA and in industry.
Role of CRO’s in Medical Innovation and Drug DevelopmentJohn Douglas
Critical medical conditions such as new threats from chronic diseases and their debilitating conditions require quick responses and consistent attempts on a global level. Therefore, when the medical equipment and pharmaceutical biotechnology companies are in need to introduce efficient and effective drugs faster to the market, that is the time when they also need partners who are able to collaborate and assure them effortless development and service delivery.
Part of the MaRS Best Practices Series - Pre-Clinical development workshop
http://www.marsdd.com/bestpractices/
Speaker: James Ault, VP Regulatory Affairs, Ricerca BioSciences
Process Analytical Technology, Quality by Design & PharmacogenomicsAjaz Hussain
Keynote address at the 2013 Scientific Conference of the Nigerian Association of Pharmacists and Pharmaceutical Scientists in the Americas (NAPPSA). The lecture attempts to 'connect the dots' between PAT and QbD to Pharmacogenomics in the context of the authors experience at the US FDA and in industry.
Role of CRO’s in Medical Innovation and Drug DevelopmentJohn Douglas
Critical medical conditions such as new threats from chronic diseases and their debilitating conditions require quick responses and consistent attempts on a global level. Therefore, when the medical equipment and pharmaceutical biotechnology companies are in need to introduce efficient and effective drugs faster to the market, that is the time when they also need partners who are able to collaborate and assure them effortless development and service delivery.
Part of the MaRS Best Practices Series - Pre-Clinical development workshop
http://www.marsdd.com/bestpractices/
Speaker: James Ault, VP Regulatory Affairs, Ricerca BioSciences
IGPA Building a Culture of Quality Ajaz Hussain_5 Sept 2015_Rferences minAjaz Hussain
Improving Confidence in Quality of Medicines . We make two products – medicine and evidence (documents) but many forget this and do not pay attention to documentation.
Level of attention to documentation is a “canary in a coal mine”
Breaches are irrational –”System 1 thinking” and cognitive biases.
Culture of Quality is familiar to all of us – a framework proposed
Quality Metrics – great idea – very much needed; but we are not yet ready for an FDA Guidance.
We must first address our collective blind spots; be confident that process validation truly ensures complexity is sufficiently reduced and that outcomes are predictable.
The Evolving Quality Expectations & Reshaping Strategy of Controls in Pharmac...Obaid Ali / Roohi B. Obaid
Seminar on "Advanced Pharmaceutical Technology & Practice to Compliance with Challenging Standards" organized by Austar, China & Morgan, Pakistan attended by over hundred participants from different pharmaceutical industries of Karachi & Lahore
Pharmaceutical Quality - The Office ofAjaz Hussain
The keynote address at the Fall meeting of the CPPR Industrial Advisory Board and the Site Directors held yesterday (27 October 2014) at Purdue University. The talk provides a perspective on the recent organizational changes announced by FDA CDER - the Office of Pharmaceutical Quality.
It is an original piece of writing. Represented thoughts are outcome of reading materials and experience as a regulator and shared to promote culture of reading, writing and managing the knowledge. All critics and comments are welcome.
Good Regulators of Pharmaceuticals (GRP) 22 October 2014Ajaz Hussain
Sharing thoughts on what makes a Good Regulator of Pharmaceuticals with pharmacy students at the Universities of Minnesota and Iowa. A point of emphasis on "we all are regulators" is explained and three areas for learning - (a) Systems and Integrative Thinking, (b) Argumentation and (c) Behavioral Economics described.
I hope you, the viewers, will also find some value in reviewing these slides. If you are a student and have some questions please feel free to drop me a email (a2zpharmsci@msn.com).
Joint San Diego Chapters CLMA AACC / May 16 2010 Mtg Robert Parsonbpstat
With closer scrutiny by public and private payers of laboratory tests and their importance to medicine, evidence for their appropriate use often is limited and their cost effectiveness too often misunderstood.
The presentation will review the expanding use of evaluation processes and methodologies by which laboratory tests are evaluated and reimbursed. Learn the strategies manufacturers, laboratory service providers, and payers employ to collect outcome and cost data to better support the effective use of new laboratory tests which in turn increases appropriate use and reimbursement. What common language, nomenclature and information should be used to present that facilitates an open, straightforward dialogue from the development, review, and delivery of evidence-based findings by manufacturers, clinical laboratories, and healthcare providers to those entities that make coverage and reimbursement decisions.
Course Objectives:
How does industry use Metrics?
FDA Challenges and Requirements and Use of Quality Metrics
Complexities of Implementation (Industry Feedback)
What does it all mean?
Key in Risk identification – systematic use of information to identify potential sources of harm (hazards)
referring to the risk question or problem description.
Enables the detection of potential problems as early as possible to plan corrective and preventive
actions
Provides indication that controls are losing effectiveness Important in achieving problem resolution and problem prevention
Another important concept of modern quality systems is the use of trending to examine processes as a whole.
Driving wrong behaviors and unintended consequence
• Establishing excessive or overly complex metrics
Comparing data that is not consistently defined or comparison of single data values
Using metrics as a quality “surrogate”
Critical Path Initiative Challenges: FDA ACPS Meeting 19 October 2004Ajaz Hussain
Each section within P2 can have an impact on the other P2 sections and similarly other sections of a submission and to CGMP’s By recognizing this as a complex design system that involves multiple attributes, goals, constraints, multidisciplinary design teams (subsystems), different degrees of uncertainty, risk tolerance, etc., we wish to find opportunities to identify robust designs and design space that provides a sound basis for risk assessment and mitigation
Similar to 2015 Dashboard of Pharmaceutical & Biologics Regulatory Sciences (20)
An article on contamination of Diethylene Glycol in Pharmaceuticals. Thanks to Dr. Ajaz S. Hussain for all teaching, sharing knowledge and supporting in professional development.
Artificial intelligence (AI) offers new opportunities to radically reinvent the way we do business. This study explores how CEOs and top decision makers around the world are responding to the transformative potential of AI.
The case study discusses the potential of drone delivery and the challenges that need to be addressed before it becomes widespread.
Key takeaways:
Drone delivery is in its early stages: Amazon's trial in the UK demonstrates the potential for faster deliveries, but it's still limited by regulations and technology.
Regulations are a major hurdle: Safety concerns around drone collisions with airplanes and people have led to restrictions on flight height and location.
Other challenges exist: Who will use drone delivery the most? Is it cost-effective compared to traditional delivery trucks?
Discussion questions:
Managerial challenges: Integrating drones requires planning for new infrastructure, training staff, and navigating regulations. There are also marketing and recruitment considerations specific to this technology.
External forces vary by country: Regulations, consumer acceptance, and infrastructure all differ between countries.
Demographics matter: Younger generations might be more receptive to drone delivery, while older populations might have concerns.
Stakeholders for Amazon: Customers, regulators, aviation authorities, and competitors are all stakeholders. Regulators likely hold the greatest influence as they determine the feasibility of drone delivery.
Specific ServPoints should be tailored for restaurants in all food service segments. Your ServPoints should be the centerpiece of brand delivery training (guest service) and align with your brand position and marketing initiatives, especially in high-labor-cost conditions.
408-784-7371
Foodservice Consulting + Design
Senior Project and Engineering Leader Jim Smith.pdfJim Smith
I am a Project and Engineering Leader with extensive experience as a Business Operations Leader, Technical Project Manager, Engineering Manager and Operations Experience for Domestic and International companies such as Electrolux, Carrier, and Deutz. I have developed new products using Stage Gate development/MS Project/JIRA, for the pro-duction of Medical Equipment, Large Commercial Refrigeration Systems, Appliances, HVAC, and Diesel engines.
My experience includes:
Managed customized engineered refrigeration system projects with high voltage power panels from quote to ship, coordinating actions between electrical engineering, mechanical design and application engineering, purchasing, production, test, quality assurance and field installation. Managed projects $25k to $1M per project; 4-8 per month. (Hussmann refrigeration)
Successfully developed the $15-20M yearly corporate capital strategy for manufacturing, with the Executive Team and key stakeholders. Created project scope and specifications, business case, ROI, managed project plans with key personnel for nine consumer product manufacturing and distribution sites; to support the company’s strategic sales plan.
Over 15 years of experience managing and developing cost improvement projects with key Stakeholders, site Manufacturing Engineers, Mechanical Engineers, Maintenance, and facility support personnel to optimize pro-duction operations, safety, EHS, and new product development. (BioLab, Deutz, Caire)
Experience working as a Technical Manager developing new products with chemical engineers and packaging engineers to enhance and reduce the cost of retail products. I have led the activities of multiple engineering groups with diverse backgrounds.
Great experience managing the product development of products which utilize complex electrical controls, high voltage power panels, product testing, and commissioning.
Created project scope, business case, ROI for multiple capital projects to support electrotechnical assembly and CPG goods. Identified project cost, risk, success criteria, and performed equipment qualifications. (Carrier, Electrolux, Biolab, Price, Hussmann)
Created detailed projects plans using MS Project, Gant charts in excel, and updated new product development in Jira for stakeholders and project team members including critical path.
Great knowledge of ISO9001, NFPA, OSHA regulations.
User level knowledge of MRP/SAP, MS Project, Powerpoint, Visio, Mastercontrol, JIRA, Power BI and Tableau.
I appreciate your consideration, and look forward to discussing this role with you, and how I can lead your company’s growth and profitability. I can be contacted via LinkedIn via phone or E Mail.
Jim Smith
678-993-7195
jimsmith30024@gmail.com
The Team Member and Guest Experience - Lead and Take Care of your restaurant team. They are the people closest to and delivering Hospitality to your paying Guests!
Make the call, and we can assist you.
408-784-7371
Foodservice Consulting + Design
2. Obaid Ali & Roohi B. Obaid,
Pharmaceutical & Biological Regulatory Sciences Forum 26 Dec 2015, Karachi
Dash Board of 2015
Pharmaceutical Regulatory Science’s Review
4. Not the view of DRAP
Current judgment of speaker
No obligation on DRAP
Regulatory experience
It has nothing to do
with any specific
commercial
product
It is just a
knowledge sharing
exercise nothing
more than that
D
I
S
C
L
A
I
M
E
R
5. Background Review of
Regulatory Sciences
Changes & Emerging shape of
Regulatory Sciences
Discussion, Case Studies &
Explanation
25. Quality Metrics
(Russell Wesdyk, Acting Director for the Office of Surveillance, OPQ, CDER, FDA
How is industry performing?
Who & what is out there?
Do we understand our industry?
What should Regulatory Authority do when they show up at the site?
Can we sum up what we have with data & transfer that data into knowledge?
26. Quality Metrics
(Russell Wesdyk, Acting Director for the Office of Surveillance, OPQ, CDER, FDA
More information is better
than less information
27. Business Model Shifting
(Monika Cahilli, Green Mountain Quality Assurance)
Increased Outsourcing
Paper Tiger does not always work
Management needs to be fully engaged in Quality Agreements
Feedback mechanism for Control Strategy
Continuous review of electronic data
28. How many data points are involved to
support the release of one product?
Learn to embrace in perfection in order to
accept residual risk
Business Model Shifting
(Monika Cahilli, Green Mountain Quality Assurance)
29. Data Integrity
(Douglas Starn, Director Enforcement & Import Operations, FDA)
Integrity & Fraud are mostly close
Lack of integrity at one area raise question about others
Ability to assure safety & efficacy is doubtful
Data accountability is the only tool
30. Data integrity issues are not always easy to
see and thus difficult to remediate
It is better to be safe than sorry…proper
control can prevent and limit data integrity
issues
Data Integrity
(Douglas Starn, Director Enforcement & Import Operations, FDA)
31. Quality & Innovations are linked
(Lisa Zboril, Vice President Regulatory Affairs, Pfizer)
Product lifecycle … what occurs in manufacturing & how
reflected in submission
Quality submission is planning, control & continuous
improvement
Early planning to target product profile and label requirement
Regular communication of uncertainties
32. Continuous improvements include
regulatory intelligence, deficiency tracking,
lessons learned & scientific rigor of data
In generic world, the key to success is being
efficient, timely and accurate
Quality & Innovations are linked
(Lisa Zboril, Vice President Regulatory Affairs, Pfizer)
33. Make the reviewer excited that they
are getting an application from you
Quality & Innovations are linked
(Ted Sherwood, Acting Director, Office of Regulatory Operations, FDA)
34. Background Review of
Regulatory Sciences
Changes & Emerging shape of
Regulatory Sciences
Discussion, Case Studies &
Explanation
35. Proposed Product Manufacturing Classification System
Right
particle
Best
process
Difficult
API
Good
API
Ref:
Lilly, GSK ……….
36. Highly Soluble &
Highly Permeable
Highly Soluble &
Less Permeable
Low Soluble &
Highly Permeable
Less Soluble &
Less Permeable
BCS
43. Breakthrough
Life saving therapy is being coming
Hepat
itis C
Cholesterol
lowering
agents
Cance
r
drugs
Rare disease
therapies
2014
41 new drugs
10 biologics
44. 2015
1st Bio-similar approval in US
Zarxio from Sandoz
Over 50 applications are in pipeline
Quick response on Ebola
A beautiful collaborative demonstration of different
organizations & countries to combat deadly virus
45. Quality remains a Challenge
Predictable & timely approval
Reduced inspection burden
Quality Metrics on way
Smart &
Progressive
vision
Able to
detect
quality
problems
before they
occur
46. Changes Evolved
• CMC from pre-clinical/clinical through review to post
approval changes & generic drug development
Changes in Review
• Continue to oversee innovators and biosimilars
Biotechnological
Products
• Quality aspect during development & approvalNew drug product
• Post-marketing changes & generic drug developmentLifecycle
• Manufacturing operation, microbiology review &
preapproval inspection
Collaborative Oversight
47. Adoption of a Risk based Model
Target oversight
where quality
failures are most
likely to harm
patients
Product
Facilities
Process
48. Footprints of knowledge is in your backyard to navigate you …
Example
Elemental impurities
Ref: Pharmaceutical Technology,
March 2015, Andrew Teasdale et al.
51. Excipients
1. Mind
(Talc)
2. Metal catalysts
(Mannitol)
3. Plant origin
(cellulose)
4. Animal origin
(lactulose)
5. Without metal
catalysts (colloidal
SiO2)
Footprints of knowledge is in your backyard to navigate you …
52. Limited solubility in DP
& limited interaction but
High metal content in
packaging
Highest risk (high conc. of
metal in packaging; high
degree of interaction b/w
packaging & DP)
Lowest risk (low conc. of
metal in packaging;
limited interaction b/w
packaging & DP)
Good solubility in DP,
intimate contact, but low
metal content in packaging
From
Packaging
MetalContentinPackaging
Metal solubility in product
R
I
S
K
I
N
P
A
C
K
A
G
I
N
G
Footprints of knowledge is in your backyard to navigate you …
53. Security of internal supply chain
Control of vendor elemental impurity specifications & elemental impurity
reporting on ingredient COA
Security of external supply chain + a quality history for each vendor
Audit history Level of complaints Recall etc.
PRIOR KNOWLEDGE IS THE WAY TO MOVE FORWARD
Footprints of knowledge is in your backyard to navigate you …
55. Industry & Regulatory Agencies on Global Watch
Lifecycle data
management &
Quality System
Innovative
strategies to meet
timeframes
Global framework
& collaborations to
secure supply chain
Drug development
& Drug Pricing
battle
Controversy on
strategies &
Science Scale
Modernization in
Manufacturing &
Quality Initiatives
Efficient generic
drug review
regulatory
framework
Policies to enhance
drug safety &
security
Reference
Jill Wechsler, 2015
56. Lifecycle data management & Quality System
Alteration in
System,
Formulation &
Test Method
Variation
submission
Costly & time
consuming
Regulatory &
Post approval
changes
Developing
International
Quality Standards
Integrations
Review,
Inspection &
Surveillance
57. Innovative strategies to meet timeframes
Expedite
development &
approval of
innovative drug
Quick results of
reviews
Innovative risk
mitigation
strategies
Less stability data
at submission
Accepting
amendment during
the review process
Increased post-
marketing
commitment
Early decision for
dosage form
Early decision for
method validation
strategies before
time
58. Global Framework & Collaborations to secure supply
Storm of counterfeit &
adulterated drugs
Over 2000 incidences
of pharmaceutical
crime reported in 2014
Theft, counterfeiting,
diversions, illegal drug
websites
Aggressive &
collaborative actions
June 2015 operation
Pangea VIII by
Interpole
Poor quality
medicines
SSFFC (Substandard,
Spurious, Falsely
Labeled, Falsified &
Counterfeit)
59. Drug Development & Drug Pricing battle
Costing
Therapeutic
value
Free
economy
Innovation
Fee Liability Profit
60. Controversy on Strategies & Science Scale
Quality Metrics Overworking Increased burden
Reduced
inspection
Reduced
regulatory burden
on post approval
Slow move
61. Modernization in Manufacturing & Quality Initiatives
More powers of
inspection
Recall power
New Inspection
approach
Unannounced
inspection
Tougher
inspections
Disregarding the
delaying, denying,
limiting or refusing
of inspections
62. Efficient Generic Drug Review Regulatory Framework
API focus Inspections
Quality &
Complaints
63. Policies to enhance Drug Safety & Security
Meningitis
outbreak
IV
Compounding
Contamination
Microbial Penicillin Standardization
65. Aseptic processing proven safe but not sterile
IncreasedseparationofPersonnel
Increased confidence in Sterility Assurance
Manual aseptic fill
Conventional aseptic fill
Barrier System
Open RABS
Closed RABS
Open Gloved Isolator
Closed Glove Isolator
Glove-less Isolator
67. Inhalation of a non-sterile product (Ribavirin powder for
solution) with microbial contamination ….
What is harm?
68. Inhalation of a non-sterile product (Ribavirin powder for
solution) with microbial contamination ….
What is harm?
Increase risk of respiratory infection
Patients are usually immuno-compromised and more
susceptible to infection
69. Inhalation of a non-sterile product (Ribavirin powder for
solution) with microbial contamination ….
What is harm?
Increase risk of respiratory infection
Patients are usually immuno-compromised and more
susceptible to infection
RECALL (Virazole Expiry date: Oct 2018)
Valeant Pharmaceuticals, USA
70. If you want to go fast, go alone
If you want to go far, go together